

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	Not Assigned
Filing Date	February 22, 2002
First Named Inventor	Oliver Yoa-Pu HU et al.
Group Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	39297-174170

JC828 U.S. PRO
10/079416
02/22/02

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE
ATTORNEYS AT LAW

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Not Assigned
		Filing Date	February 22, 2002
		First Named Inventor	Oliver Yoa-Pu HU et al.
		Group Art Unit	Not Assigned
		Examiner Name	Not Assigned
		Attorney Docket Number	39297-174170
Sheet	2	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Handwritten vertical line]	AA	Xiao-Yan Li et al.; Retinoic acid antagonizes basal as well as coal tar and glucocorticoid-induced cytochrome P4501A1 expression in human skin; Carcinogenesis 1995, P 519-524, Vol. 16, No. 3	
	AB	Aleksandra Pastrakuljic et al.; Distinction of CYP1A1 and CYP1A2 Activity by Selective Inhibition Using Fluvoxamine and Isosafrole; Biochemical Pharmacology, 1997, P 531-538, Vol. 53	
	AC	Ilya B. Tsyrllov et al.; Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids; Biochimica et Biophysica Acta, 1994, P 325-335, Vol. 1205	
	AD	Kai S. Lee; Ibutilide, a New Compound with Potent Class III Antiarrhythmic Activity, Activates a Slow Inward Na ⁺ Current in Guinea Pig Ventricular Cells; The Journal of Pharmacology and Experimental Therapeutics, 1992, P 99-108, Vol. 262, No. 1	
	AE	M.T. Obermeier et al.; Effects of bioflavonoids on hepatic P450 activities; Xenobiotica, 1995, P 575-584, Vol. 25, No. 6	
	AF	S.E. Nielsen et al.; In vitro biotransformation of flavonoids by rat liver microsomes; Xenobiotica, 1998, P 389-401, Vol. 28, No. 4	
	AG	Henry P. Ciolino et al.; Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially; Biochem. J., 1999, P 715-722, Vol. 340	
	AH	R. Edenharder et al.; The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study; Mutation Research, 1997, P 21-32, Vol. 379	
	AI	S. Hegstad et al.; Characterization of metabolites of benz(j)aceanthrylene in faeces, urine and bile from rat; Xenobiotica, 1999, P 1257-1272, Vol. 29, No. 12	
	AJ	A. Galijatovic et al.; Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells; Xenobiotica, 1999, P 1241-1256, Vol. 29, No. 12	
	AK	Oliver Merk et al.; Characterization of SV40-transformed xeroderma pigmentosum cell lines for their usability in HPRT mutation studies; Mutagenesis, 1997, P 391-395, Vol. 12, No. 5	

Examiner Signature	[Handwritten Signature]	Date Considered	12/10/02
-----------------------	-------------------------	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE
ATTORNEYS AT LAW

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number		Not Assigned			
Filing Date		February 22, 2002			
First Named Inventor		Oliver Yoa-Pu HU et al.			
Group Art Unit		Not Assigned			
Examiner Name		Not Assigned			
Attorney Docket Number		39297-174170			
Sheet	3	of	3		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	AL	I. Duarte Silva et al.; Involvement of rat cytochrome 1A1 in the biotransformation of kaempferol to quercetin: relevance to the genotoxicity of kaempferol; Mutagenesis, 1997, P 383-390, Vol. 12, No. 5	
✓	AM	M. Paolini et al.; Effect of liquorice and glycyrrhizin on rate liver carcinogen metabolizing enzymes; Elsevier, 1999, P 35-42, Vol. 145	
✓	AN	Hiroshi Yamazaki et al.; Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and -ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes; Journal of Chromatography B, 1999, P 13-19, Vol. 721	
✓	AO	Jukka Maenpaa et al.; Differential Inhibition of Coumarin 7-Hydroxylase Activity in Mouse and Human Liver Microsomes; Biochemical Pharmacology, 1993, P 1035-1042, Vol. 45, No. 5	
✓	AP	S.E. Nielsen et al.; In vitro biotransformation of flavonoids by rat liver microsomes; Xenobiotica, 1998, P 389-401, Vol. 28, No. 4	

Examiner Signature		Date Considered	11/10/02
--------------------	--	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE
ATTORNEYS AT LAW